Summary
This study demonstrates that three interdependent gene signatures—reflecting cell cycle, hypoxia, and mTOR pathway activity—translate into a measurable pathologic feature (tumour necrosis) in lung adenocarcinoma and provide independent risk stratification for disease relapse and survival in operable and stage I patients. The findings suggest that molecular pathway signatures can be operationalised as prognostic biomarkers by mapping to histopathologic features, potentially improving clinical risk assessment beyond conventional staging.
UK applicability
The findings may inform UK clinical practice in lung cancer prognostication and patient stratification for adjuvant therapy consideration, though applicability would depend on integration with National Health Service diagnostic pathways and validation in UK patient populations.
Key measures
Gene signature scores (cell cycle, hypoxia, mTOR pathways); tumour necrosis presence/absence; overall survival; relapse-free survival; protein expression levels from The Cancer Genome Atlas and Cancer Protein Atlas datasets
Outcomes reported
The study investigated whether three gene signatures (cell cycle, hypoxia, and mTOR) translate into the pathologic feature of tumour necrosis and predict disease relapse and survival outcomes in patients with stage I lung adenocarcinoma. Gene signature activities and their correlation with tumour necrosis presence were measured across multiple patient cohorts using genomic and proteomic data.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.